« Home « Kết quả tìm kiếm

Disease progression

Tìm thấy 20+ kết quả cho từ khóa "Disease progression"

Predicting disease progression in advanced non-small cell lung cancer with circulating neutrophil-derived and platelet-derived microparticles

tailieu.vn

We found that circulating NMPs and PMPs independ- ently predicted disease progression in advanced NSCLC, and combination with NLR to build a predictive model. for disease progression effectively screened 80.8% of pa- tients with disease progression.

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer

tailieu.vn

Conclusion: In mCRC patients who experienced early progression in first-line chemotherapy, second-line chemotherapy showed poor clinical outcomes regardless use of anti-angiogenic agents.. Keywords: Metastatic colorectal cancer, Bevacizumab continuation beyond progression, Early disease progression, Second-line chemotherapy.

Neurochemical Mechanisms in Disease P35

tailieu.vn

Studies with DNA microarrays have suggested that the presence of the disease protein in SCA1-transgenic mice results in major changes in the expression of nine genes during disease progression. Interestingly, five of these genes centered on glutamate signaling in Purkinje cells (Serra et al., 2004)..

Subtype-Independent ANP32E Reduction During Breast Cancer Progression in Accordance with Chromatin Relaxation

tailieu.vn

We therefore investigated chromatin accessibility differences in accordance with disease progression in our dataset.. Remarkably, average chromatin accessibility levels within each signature differed across tumor stages (Fig. 3 Chromatin Accessibility in FOX motifs and Signature 2 Regions Associate with Tumor Progression Stages.

Transcriptome sequencing and multi-plex imaging of prostate cancer microenvironment reveals a dominant role for monocytic cells in progression

tailieu.vn

A deeper understanding of the tumour microenvironment is needed to identify the key drivers of disease progression and reveal novel therapeutic opportunities.. Results: In this study, the experimental enrichment of selected cell-types, the development of a Bayesian inference model for continuous differential transcript abundance, and multiplex immunohistochemistry permitted us to define the transcriptional landscape of the prostate cancer microenvironment along the disease progression axis..

Interstitial lung disease is a dominant feature in patients with circulating myositis-specifc antibodies

tailieu.vn

The mean duration of follow- up for determining disease progression among survivors was similar between the two groups (27.0 months for isolated ILD vs. 28.5 months for PM/DM-ILD, p = 0.79).. When death or disease progression was used as a com- posite endpoint, the difference between the two groups was not statistically significant, but there was a trend towards improved progression-free survival in the PM/.

Circulating MiR-1290 as a potential diagnostic and disease monitoring biomarker of human gastrointestinal tumors

tailieu.vn

Relative miR-1290 levelsWeight (g). 5 Circulating miR-1290 is a promising biomarker for disease surveillance. e The fluctuation of circulating miR-1290 during disease progression and drug treatment in the xenograft mouse model. f Changes of serum miR-1290 levels in CRC patients after surgery were determined by RT-qPCR ( n = 10. miR-1290 contributes to colorectal cancer cell proliferation by targeting INPP4B.

Effects of anesthetic method on inflammatory response in patients with Parkinson’s disease: A randomized controlled study

tailieu.vn

Biomarkers in Parkinson ’ s disease: advances and strategies. Williams-Gray CH, Wijeyekoon R, Yarnall AJ, Lawson RA, Breen DP, Evans JR, et al. Serum immune markers and disease progression in an incident Parkinson ’ s disease cohort (ICICLE-PD). The innate immune system in Parkinson ’ s disease:. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson ’ s disease.

Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease

tailieu.vn

Conclusions: Changes of intestinal bacterial microbiota in CHD-NAFLD patients may be important factors affecting the degree of metabolic disorder, which may be one of the important reasons for the worse clinical outcome and disease progression in CHD-NAFLD patients than in CHD patients.. The intestinal microbiota in CHD-NAFLD patients might be different from that in CHD patients.

Accelerated hematopoietic mitotic aging measured by DNA methylation, blood cell lineage, and Parkinson’s disease

tailieu.vn

Increased epigenetic age and granulocyte counts in the blood of Parkinson ’ s disease patients. Parkinson ’ s disease is associated with DNA methylation levels in human blood and saliva. Longitudinal Epigenome-Wide Methylation Study of Cognitive Decline and Motor Progression in Parkinson ’ s Disease. DNA methylation changes associated with Parkinson ’ s disease progression:. Of Pesticides and Men: a California Story of Genes and Environment in Parkinson ’ s Disease.

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: A retrospective study

tailieu.vn

Furthermore, no patient who developed oligo-residual disease after EGFR-TKI therapy induction underwent LAT.. 1 Oligo-residual disease and PD limited to residual sites. The criteria and legends for Oligo-residual disease. PFS was calculated from the residual disease evalua- tion to the first evidence of disease progression or death from any cause and estimated using the Kaplan-Meier method.

Neurochemical Mechanisms in Disease P37

tailieu.vn

Ona VO, Li M, Vonsatell J-P, Andrews LJ, Khan SQ, Chung WM, Frey AS, Menon AS, Li XJ, Stieg PE, Yuan J, Penney JB, Young AB, Cha JH, Friedlander RM (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington’s disease.

Survey on some clinical and subclinical features of eye lesions and trab concentration in patients with graves’ disease

tailieu.vn

In order to have an understanding of the disease, we conduct a research project with the aim: To survey some clinical and subclinical features of eye lesions and TRAb index in patients with Graves’ disease.. 82 patients with Graves’ ophthalmopathy.. diagnose Graves’ disease and manifestations of Graves’ ophthalmopathy.. Questioning: take notes on the history of the disease, disease progression, functional symptoms such as photophobia, lacrimation, diplopia.. CT-scan of the eye sockets:.

The DANTE trial protocol: A randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma

tailieu.vn

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. doi.org/10.1093/annonc/mdz110.

Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer

tailieu.vn

The patients with higher mTBI at baseline in this cohort were nearly 3 times more likely to experience disease progression than the patients with lower mTBI.. The patients with reduction in mTBI after treatment had a 78% lower risk of disease progression than the pa- tients without. Inexplicably, 2 patients with reduction in ctDNA after 4 cycles of treatment experienced disease progres- sion instead of response to therapy.

Chapter 104. Acute and Chronic Myeloid Leukemia (Part 15)

tailieu.vn

However, delaying BMT for high-risk patients (Sokal/Hasford criteria) may result in disease progression. SCT after disease progression is associated with poorer outcome.. Therefore, we recommend close monitoring of imatinib response, especially in these patients (Table 104-4).

Multicenter randomized controlled trial and registry study to assess the safety and efficacy of the NanoKnife® system for the ablation of stage 3 pancreatic adenocarcinoma: Overview of study protocols

tailieu.vn

Subjects who do not have disease progression and have not died, will be censored at the date of last tumor assessment. Subjects with a single missing radiologic or clinical assessment immediately prior to a visit with doc- umented disease progression (or death) will be analyzed as a PFS event at the time of the clinical or radiologic as- sessment that shows progression.

Genetic diversity of Escherichia coli in gut microbiota of patients with Crohn’s disease discovered using metagenomic and genomic analyses

tailieu.vn

Finally, is the species a primary cause of Crohn’s disease contributing to the on- set of the disease via interplay with the other risk factors or a secondary “first available” species emerging in an environment of general gut imbalance that exacerbates disease progression?. The species-level profiling of the microbiota showed pro- nounced dysbiosis as a prevalence of various abnormal community types driven by opportunistic pathogens (Fig.

Efficacy of early antifibrotic treatment for idiopathic pulmonary fbrosis

tailieu.vn

Methods: We compared survival and disease progression between patients with IPF with Japanese Respiratory Soci- ety (JRS) disease severity system stage I with and without oxygen desaturation on the 6-min walk test (6MWT) and increased the gender–age–physiology (GAP) staging. We examined the efficacy of antifibrotic drugs in patients with early-stage IPF..

Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: A real-world chart review study

tailieu.vn

The median time to disease progression was not reached among patients who initiated daratumumab in 1 L. Among patients who initiated daratumumab in 2 L, median time to disease progression was 27.8 months.. Among patients who initiated daratumumab in 3 L+, median time to disease progression was 12.0 months.. Kaplan-Meier rates of PFS at 12 months were and 53.1% among patients who initiated daratumumab in 1 L, 2 L, and 3 L+, respectively (see Fig.